PHASE 2 DATA FOR CRIZOTINIB (PF-02341066) IN ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PROFILE 1005

被引：0
|
作者：
Riely, Gregory J. [1 ]
Kim, Dong-Wan [2 ]
Crino, Lucio [3 ]
Janne, Pasi A. [4 ]
Blackhall, Fiona H. [5 ]
Camidge, David R. [6 ]
Hirsh, Vera [7 ]
Mok, Tony S. K. [8 ]
Solomon, Ben [9 ]
Soria, Jean-Charles
Park, Keunchil [10 ]
Gadgeel, Shirish M. [11 ]
Martins, Renato G. [12 ]
Han, Ji-Youn
De Pas, Tommaso [13 ]
Bottomley, Andrew
Polli, Anna
Petersen, Jennifer A. [14 ]
Tassell, Vanessa R. [15 ]
Shaw, Alice T. [16 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Azienda Osped Perugia, Div Med, Perugia, Italy
[4] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
[5] Christie NHS Fdn Trust, Manchester, Lancs, England
[6] Univ Colorado Denver, Aurora, CO 80045 USA
[7] McGill Univ, Ctr Hlth, Dept Oncol, Montreal, PQ H3A 2T5, Canada
[8] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
[9] Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Vic, Australia
[10] Sungkyunkwan Univ, Sch Med, Dept Med, Div Hem Onc, Seoul, South Korea
[11] Ayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[12] Univ Washington, Seattle, WA 98195 USA
[13] European Inst Oncol, Thorac Oncol Unit, Milan, Italy
[14] Pfizer Oncol, Hlth Econ & Global Outcomes Res, New York, NY USA
[15] Pfizer Oncol, Clin Res & Dev, New York, NY USA
[16] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Crizotinib; PF-02341066; Non-small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S411 / S412
页数：2
相关论文
共 50 条
  • [31] CRIZOTINIB VERSUS PEMETREXED OR DOCETAXEL CHEMOTHERAPY IN ADVANCED, ALK-POSITIVE NON-SMALL CELL LUNG CANCER: A RANDOMIZED PHASE III STUDY (PROFILE 1007)
    Kim, Dong-wan
    Janne, Pasi A.
    Nakagawa, Kazuhiko
    Seto, Takashi
    Crino, I.
    Ahn, Myung-ju
    De Pas, T. M.
    Besse, Benjamin
    Solomon, Ben
    Blackball, Fiona
    Wu, Yi-long
    Thomas, Michael
    O'Byrne, Kenneth J.
    Moro-Sibilot, Denis
    Camidge, D. R.
    Hirsh, Vera
    Mok, Tony S. K.
    Tassell, Vanessa
    Polli, A.
    Shaw, A. T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S445 - S446
  • [32] Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Vizcarrondo, F. R.
    Patel, S. P.
    Pennell, N. A.
    Pakkala, S.
    West, H.
    Kratzke, R.
    Tarazi, J.
    Wilner, K.
    Polli, A.
    Tan, W.
    Liu, Y.
    Valota, O.
    Piperdi, B.
    Reckamp, K. L.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [33] Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
    Biagio Ricciuti
    Andrea De Giglio
    Carmen Mecca
    Cataldo Arcuri
    Sabrina Marini
    Giulio Metro
    Sara Baglivo
    Angelo Sidoni
    Guido Bellezza
    Lucio Crinò
    Rita Chiari
    [J]. Medical Oncology, 2018, 35
  • [34] Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
    Ricciuti, Biagio
    De Giglio, Andrea
    Mecca, Carmen
    Arcuri, Cataldo
    Marini, Sabrina
    Metro, Giulio
    Baglivo, Sara
    Sidoni, Angelo
    Bellezza, Guido
    Crino, Lucio
    Chiari, Rita
    [J]. MEDICAL ONCOLOGY, 2018, 35 (05)
  • [35] Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC)
    Solomon, Benjamin J.
    Gettinger, Scott N.
    Riely, Gregory J.
    Gadgeel, Shirish M.
    Nokihara, Hiroshi
    Han, Ji-Youn
    Hida, Toyoaki
    Satouchi, Miyako
    Baldini, Editta
    Siena, Salvatore
    Yamamoto, Nobuyuki
    Horn, Leora
    Tassell, Vanessa Roberts
    Polli, Anna
    Camidge, D. Ross
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non-Small Cell Lung Cancer?
    Crystal, Adam S.
    Shaw, Alice T.
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4479 - 4481
  • [37] Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
    Karachaliou, Niki
    Fernandez Bruno, Manuel
    Paulina Bracht, Jillian Wilhelmina
    Rosell, Rafael
    [J]. ONCOTARGETS AND THERAPY, 2019, 12 : 4567 - 4575
  • [38] Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance
    Xu, Haiyan
    Yang, Guangjian
    Yang, Lu
    Yang, Yaning
    Ma, Di
    Li, Junling
    Hao, Xuezhi
    Xing, Puyuan
    Wang, Yan
    [J]. THORACIC CANCER, 2019, 10 (05) : 1096 - 1102
  • [39] PRELIMINARY EXPOSURE RESPONSE (ER) ANALYSIS OF CRIZOTINIB IN PATIENTS WITH ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER
    French, J.
    Tan, W. W.
    Kang, D.
    Bello, A.
    Selaru, P.
    Wilner, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S65 - S65
  • [40] PRELIMINARY EXPOSURE RESPONSE (ER) ANALYSIS OF CRIZOTINIB IN PATIENTS WITH ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER
    French, J.
    Tan, W.
    Kang, D.
    Bello, A.
    Selaru, P.
    Wilner, K.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S132 - S132
12345